ALB and neoplasm: Humabody-based therapeutics have shown preclinical evidence of superior tumour penetration vs. traditional monoclonal antibodies [29], likely due to smaller physical size and potentially also tissue partitioning aided by both active and passive transport mediated by albumin binding [30]; these findings await evaluation in human patients.